Gedeon Richter Strikes $16.5m Global Tocilizumab Deal

Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax

Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.

Tocilizumab_Injections
The deal provides Richter with a rival to Actemra/RoActemra • Source: Shutterstock

Gedeon Richter has struck a deal worth $16.5m with Taiwanese biotech firm Mycenax to gain global development, manufacturing and commercialization rights to the company’s proposed tocilizumab biosimilar version of Roche’s Actemra/RoActemra.

The asset purchase agreement covers “cell lines, intellectual property rights, technology know-how and data generated by Mycenax,” with the $16.5m...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business